Issued 2026-08-13 at $25.30 · now $25.02 (2026-08-13, −1.1% since)
Based on its own history, a month from the 2026-08-13 close, TYRA has typically landed between $18.33 and $34.49 — a range of −27.5% to +36.3% from the issuance price $25.30.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
1,212 overlapping 1 month windows · 2021-09-15 – 2026-07-15 · basis climatology · forecast (batch). Probability up 53.8% (90% CI 51.6–56.0%, ≈1,400 obs).
The cone is anchored at the 2026-08-13 issuance close ($25.30) — the price the forecast resolves against on 2026-09-11, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where TYRA has typically landed a month from the 2026-08-13 close of $25.3 — the range is history, not a prediction.
- now $25.02 (-1.1%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $25.6 (+1.2%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $22.54–$28.65
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $18.33–$34.49
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2021-11-17 | −53.3% | −53.3% | +0.0% |
| 2021-11-16 | −50.2% | −50.2% | +0.0% |
| 2021-11-18 | −48.7% | −48.7% | +5.3% |
| 3 best | |||
| 2021-10-06 | +128.2% | +0.0% | +128.2% |
| 2021-10-05 | +115.2% | +0.0% | +115.2% |
| 2023-01-06 | +97.5% | +0.0% | +97.5% |
1,212 overlapping windows · 2021-09-15 – 2026-08-13 · not cherry-picked
Pending catalysts
- November 2026 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (source, as of 2026-08-14)
- February 2028 — Trial primary completion: Phase 2 primary completion: Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (source, as of 2026-08-14)
- January 2030 — Trial primary completion: Phase 2 primary completion: A Study of TYRA-300 in Children With Achondroplasia: BEACH301 (source, as of 2026-08-14)
- October 2030 — Trial primary completion: Phase 2 primary completion: Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma (source, as of 2026-08-14)
Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~5 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Company insiders iOpen-market share purchases and sales by the company's own officers and directors, by filing date.
Last 90 days · as of 2026-08-13 · point-in-time by filing date
No insider transactions on record in the last 90 days.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. Full terms.